盐酸多奈哌齐治疗阿尔茨海默病患者的疗效观察  

Clinical observation of Donepezil HCL in treatment of Alzheimer's Diseases

作　　者：林杭[1] 杨正辉[1] 刘榆[1] 王建[1] 陈琳[1] 

机构地区：[1]成都军区总医院神经内科,四川成都610083

出　　处：《中国生化药物杂志》2014年第5期64-65,共2页Chinese Journal of Biochemical Pharmaceutics

基　　金：国家自然科学基金(81071003)

摘　　要：目的研究盐酸多奈哌齐治疗阿尔茨海默病患者的疗效观察,并对其安全性进行评价。方法选取2010年7月~2013年7月成都军区总医院神经内科收治的48例阿尔茨海默病患者为研究对象,按照随机数字表法分为研究组(n=24)和对照组(n=24),对照组给予常规药物联合尼膜同治疗,研究组给予常规药物联合盐酸多奈哌齐进行治疗,观察比较2组患者临床疗效及不良反应。结果治疗后研究组患者ADL评分、MMSE评分和总有效率均显著高于对照组,2组比较差异有统计学意义(P<0.05);研究组不良反应发生率明显低于对照组,2组比较差异有统计学意义(P<0.05)。结论盐酸多奈哌齐可以提高阿尔茨海默病的临床疗效。Objective To study the clinical efficacy of Donepezil HCL on alzheimer's disease,and evaluate its safety. Methods 48 cases with alzheimer diseases admitted in General Hospital of Chengdu Military Region from July,2010 to July,2013 were selected as research subjects,and divided into research group and control group,each had 24 cases. Control group were received Nimotopine on the basis of conventional therapy,research group were received Donepezil HCL on the basis of conventional therapy,clinical efficacy and adverse reactions in two groups were observed and compared. Results After treatment,ADL score,MMSE scores and total efficacy in research group were higher than that in control group,the differences between two groups were significant( P < 0. 05),the incidence of adverse reactions in research group were lower than that in control group,the differences between two groups were significant(P < 0. 05). Conclusion Donepezil HCL has good clinical efficacy in treatment of alzheimer's disease.

关 键 词：盐酸多奈哌齐 阿尔茨海默病 疗效 安全性 

分 类 号：R745.1[医药卫生—神经病学与精神病学]